TipRanks
Advertisement
Advertisement

COYA Stock Latest News

Coya launches open-label ALS extension, reprioritizes pipeline
Company AnnouncementsCoya launches open-label ALS extension, reprioritizes pipeline
5d ago
8K
COYA
Coya Therapeutics to initiate OLE of Phase 2/3 ALSTARS trial of COYA 302
PremiumThe Fly
Coya Therapeutics to initiate OLE of Phase 2/3 ALSTARS trial of COYA 302
5d ago
COYA
Coya: ALSTARS Trial Progress and Strategic Partnership Underpin Buy Rating and Unchanged $18 Price Target
PremiumRatings
Coya: ALSTARS Trial Progress and Strategic Partnership Underpin Buy Rating and Unchanged $18 Price Target
13d ago
COYA
Coya Therapeutics Completes Enrollment in ALSTARS ALS Trial
PremiumCompany Announcements
Coya Therapeutics Completes Enrollment in ALSTARS ALS Trial
14d ago
8K
COYA
Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302
PremiumThe Fly
Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302
14d ago
COYA
Analyst Maintains Buy on Coya Therapeutics, Reiterates Unchanged $18 Price Target Amid ALS Trial Momentum
PremiumRatingsAnalyst Maintains Buy on Coya Therapeutics, Reiterates Unchanged $18 Price Target Amid ALS Trial Momentum
24d ago
COYA
Coya Therapeutics Advances COYA 302 ALS Phase 2/3 Trial
Premium
Company Announcements
Coya Therapeutics Advances COYA 302 ALS Phase 2/3 Trial
1M ago
8K
COYA
Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial
Premium
The Fly
Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial
1M ago
COYA
Ram Selvaraju Reiterates Buy on Coya with Unchanged $18 Price Target as New COYA 303 Data Highlight Additional Upside Potential
PremiumRatings
Ram Selvaraju Reiterates Buy on Coya with Unchanged $18 Price Target as New COYA 303 Data Highlight Additional Upside Potential
1M ago
COYA
Coya announces publication of preclinical study on effects of COYA 303
PremiumThe Fly
Coya announces publication of preclinical study on effects of COYA 303
1M ago
COYA
Coya Therapeutics reports Q2 EPS (28c), consensus (36c)
PremiumThe Fly
Coya Therapeutics reports Q2 EPS (28c), consensus (36c)
2M ago
COYA
Roth Capital biopharmaceuticals analyst holds a webinar
PremiumThe Fly
Roth Capital biopharmaceuticals analyst holds a webinar
3M ago
BIIB
COYA
Coya Therapeutics Shareholders Back Board, Auditor at Meeting
PremiumCompany AnnouncementsCoya Therapeutics Shareholders Back Board, Auditor at Meeting
4M ago
8K
COYA
Coya Therapeutics initiates first cohort of patients in ALSTARS trial
Premium
The Fly
Coya Therapeutics initiates first cohort of patients in ALSTARS trial
4M ago
COYA
Coya Therapeutics initiated with a Buy at Roth Capital
Premium
The Fly
Coya Therapeutics initiated with a Buy at Roth Capital
5M ago
COYA
Coya Therapeutics Establishes $30 Million ATM Equity Program
PremiumCompany Announcements
Coya Therapeutics Establishes $30 Million ATM Equity Program
5M ago
8K
COYA
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
PremiumCompany Announcements
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
5M ago
8K
COYA
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
PremiumThe Fly
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
5M ago
COYA
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
PremiumThe Fly
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
5M ago
COYA
Coya Therapeutics announces publication of research on COYA 302
PremiumThe FlyCoya Therapeutics announces publication of research on COYA 302
6M ago
COYA
Coya Therapeutics Announces Leadership Changes and New Director
Premium
Company Announcements
Coya Therapeutics Announces Leadership Changes and New Director
7M ago
8K
COYA
Coya Therapeutics Executive Chairman Howard Berman steps down
Premium
The Fly
Coya Therapeutics Executive Chairman Howard Berman steps down
7M ago
COYA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >